Entellus Medical (NASDAQ:ENTL) will post its quarterly earnings results after the market closes on Monday, February 19th. Analysts expect Entellus Medical to post earnings of ($0.44) per share for the quarter.

Entellus Medical (NASDAQ:ENTL) opened at $24.00 on Monday. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $25.58. The company has a market capitalization of $611.38, a price-to-earnings ratio of -18.75 and a beta of -0.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.71 and a current ratio of 1.92.

In other Entellus Medical news, VP Thomas P. Williamson sold 2,449 shares of the firm’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $24.08, for a total value of $58,971.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Robert S. White sold 3,471 shares of the firm’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $24.01, for a total value of $83,338.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,942 shares of company stock worth $2,599,658. 7.70% of the stock is owned by insiders.

A hedge fund recently raised its stake in Entellus Medical stock. State Street Corp raised its holdings in Entellus Medical Inc (NASDAQ:ENTL) by 26.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,856 shares of the medical technology company’s stock after buying an additional 29,386 shares during the period. State Street Corp owned about 0.56% of Entellus Medical worth $2,333,000 as of its most recent SEC filing. 74.02% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently commented on ENTL shares. William Blair lowered Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research lowered Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. TheStreet upgraded Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $17.00 target price on shares of Entellus Medical in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. Entellus Medical presently has a consensus rating of “Hold” and an average price target of $19.25.

ILLEGAL ACTIVITY NOTICE: “Entellus Medical (ENTL) to Release Earnings on Monday” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://theolympiareport.com/2018/02/12/entellus-medical-entl-to-release-earnings-on-monday.html.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Earnings History for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.